Department of Oral Medicine, Oral and Maxillofacial Center, Medical Corps, Israel Defense Forces, Tel-Hashomer and Department of Oral Medicine, Hebrew University-Hadassah School of Dental Medicine and Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Aust Dent J. 2012 Sep;57(3):388-92. doi: 10.1111/j.1834-7819.2012.01717.x. Epub 2012 Aug 5.
The risk of osteonecrosis in patients treated with bisphosphonates is well known and guidelines intended to prevent this complication have been established and accepted. Bisphosphonate related osteonecrosis of the jaws (BRONJ) is a unique condition in which even past administration of medication may be of current and future relevance. We present a case of BRONJ in the maxilla after dental implant placement. The patient suffered from osteoporosis and had been treated with oral alendronate sodium in the past. However, the medication was stopped two years before implant placement, and the treating dentist was unaware of the patient's past bisphosphonate use. Prevention of BRONJ is based on identifying at-risk patients, and then avoiding or modifying dentoalveolar surgical procedures in these individuals. Nevertheless, there seems to be some difficulties identifying patients at risk. We present some of the challenges that impede thorough assessment of a patient's medical background (review of systems) in the dental office, and suggest possible solutions.
接受双膦酸盐治疗的患者发生骨坏死的风险是众所周知的,已经制定并接受了旨在预防这种并发症的指南。双膦酸盐相关性下颌骨坏死(BRONJ)是一种独特的疾病,即使是过去的药物治疗也可能与当前和未来有关。我们报告了一例上颌骨牙科种植术后发生 BRONJ 的病例。该患者患有骨质疏松症,过去曾接受过口服阿伦膦酸钠治疗。然而,在植入物放置前两年停止了药物治疗,且治疗牙医不知道患者过去曾使用过双膦酸盐。BRONJ 的预防基于识别高危患者,然后避免或修改这些患者的牙槽外科手术。然而,似乎存在一些困难来识别有风险的患者。我们提出了一些在牙科诊室中妨碍全面评估患者病史(系统回顾)的挑战,并提出了一些可能的解决方案。